The Synovial Sarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Synovial Sarcoma. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued products.

GlobalData tracks 57 drugs in development for Synovial Sarcoma by 50 companies/universities/institutes. The top development phase for Synovial Sarcoma is phase ii with 24 drugs in that stage. The Synovial Sarcoma pipeline has 53 drugs in development by companies and four by universities/ institutes. Some of the companies in the Synovial Sarcoma pipeline products market are: Immatics, Pharma Mar and Jiangsu Hengrui Medicine.

The key targets in the Synovial Sarcoma pipeline products market include Cells Expressing Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors (Cancer/Testis Antigen 130 or Opa Interacting Protein 4 or OIP4 or Preferentially Expressed Antigen Of Melanoma or PRAME).

The key mechanisms of action in the Synovial Sarcoma pipeline product include Cytotoxic To Cells Expressing Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) with seven drugs in Phase II. The Synovial Sarcoma pipeline products include nine routes of administration with the top ROA being Intravenous and 12 key molecule types in the Synovial Sarcoma pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.

Synovial Sarcoma overview

Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

For a complete picture of Synovial Sarcoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.